Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Tower Bridge Advisors

Tower Bridge Advisors lessened its stake in Becton, Dickinson and Company (NYSE:BDX) by 1.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 100,811 shares of the medical instruments supplier’s stock after selling 1,243 shares during the quarter. Becton, Dickinson and comprises approximately 1.8% of Tower Bridge Advisors’ investment portfolio, making the stock its 10th biggest holding. Tower Bridge Advisors’ holdings in Becton, Dickinson and were worth $24,512,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Kempen Capital Management N.V. bought a new position in Becton, Dickinson and during the 4th quarter worth approximately $29,000. Sage Private Wealth Group LLC acquired a new stake in Becton, Dickinson and during the 4th quarter worth approximately $37,000. Fort Pitt Capital Group LLC acquired a new stake in shares of Becton, Dickinson and in the fourth quarter valued at approximately $38,000. Mcmillion Capital Management Inc. acquired a new stake in shares of Becton, Dickinson and in the fourth quarter valued at approximately $40,000. Finally, Mascoma Wealth Management LLC acquired a new position in Becton, Dickinson and during the first quarter worth $41,000. Hedge funds and other institutional investors own 83.51% of the company’s stock.

Shares of BDX traded down $1.96 during mid-day trading on Friday, hitting $243.45. 16,084 shares of the company’s stock traded hands, compared to its average volume of 1,374,115. The company has a quick ratio of 1.32, a current ratio of 1.86 and a debt-to-equity ratio of 0.71. Becton, Dickinson and Company has a 1 year low of $219.50 and a 1 year high of $284.97. The stock has a market cap of $70.80 billion, a price-to-earnings ratio of 43.31, a P/E/G ratio of 2.11 and a beta of 0.76. The business has a 50-day simple moving average of $246.81.

Becton, Dickinson and (NYSE:BDX) last posted its earnings results on Wednesday, May 5th. The medical instruments supplier reported $3.19 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.04 by $0.15. Becton, Dickinson and had a return on equity of 15.53% and a net margin of 8.98%. The firm had revenue of $4.91 billion for the quarter, compared to analysts’ expectations of $4.88 billion. During the same period in the previous year, the firm earned $2.55 earnings per share. The business’s revenue was up 15.4% compared to the same quarter last year. Equities research analysts forecast that Becton, Dickinson and Company will post 12.81 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 30th. Investors of record on Wednesday, June 9th will be given a dividend of $0.83 per share. The ex-dividend date is Tuesday, June 8th. This represents a $3.32 annualized dividend and a dividend yield of 1.36%. Becton, Dickinson and’s dividend payout ratio is presently 32.55%.

In related news, Director Claire Fraser sold 390 shares of Becton, Dickinson and stock in a transaction that occurred on Thursday, May 27th. The stock was sold at an average price of $241.36, for a total transaction of $94,130.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 0.76% of the company’s stock.

BDX has been the subject of several research analyst reports. SVB Leerink lowered their target price on Becton, Dickinson and from $270.00 to $260.00 and set a “market perform” rating for the company in a research note on Friday, May 7th. Barclays initiated coverage on Becton, Dickinson and in a research note on Monday, May 24th. They issued an “equal weight” rating and a $270.00 price objective for the company. Six equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Becton, Dickinson and has a consensus rating of “Hold” and a consensus price target of $276.67.

Becton, Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

See Also: What is the CAC 40 Index

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.